News
AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...
Colin P.N. Dinney, MD, provides some background on translational analyses from the BOND-003 and CORE-001 trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback